SG168451A1 - Quarternary ammonium compounds and their use as antimuscarinic agents - Google Patents

Quarternary ammonium compounds and their use as antimuscarinic agents

Info

Publication number
SG168451A1
SG168451A1 SG200905309-1A SG2009053091A SG168451A1 SG 168451 A1 SG168451 A1 SG 168451A1 SG 2009053091 A SG2009053091 A SG 2009053091A SG 168451 A1 SG168451 A1 SG 168451A1
Authority
SG
Singapore
Prior art keywords
ammonium compounds
quarternary ammonium
antimuscarinic agents
trifluoromethyl
compound
Prior art date
Application number
SG200905309-1A
Other languages
English (en)
Inventor
Ivan Richards
Sue K Cammarata
Craig D Wegner
Michael Hawley
Mark P Warchol
Mark Kontny
Walter Morozowich
Karen P Kolbasa
Malcolm W Moon
Dominique Bonafoux
Sergey G Wolfson
Patrick J Lennon
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of SG168451A1 publication Critical patent/SG168451A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/66Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with quaternised amino groups bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/26Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C219/28Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG200905309-1A 2001-10-26 2002-10-25 Quarternary ammonium compounds and their use as antimuscarinic agents SG168451A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34893001P 2001-10-26 2001-10-26
US36197902P 2002-03-06 2002-03-06
US39152102P 2002-06-25 2002-06-25

Publications (1)

Publication Number Publication Date
SG168451A1 true SG168451A1 (en) 2011-02-28

Family

ID=27407868

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200905309-1A SG168451A1 (en) 2001-10-26 2002-10-25 Quarternary ammonium compounds and their use as antimuscarinic agents

Country Status (16)

Country Link
US (2) US6890920B2 (https=)
EP (1) EP1461306B1 (https=)
JP (1) JP3981357B2 (https=)
AT (1) ATE418534T1 (https=)
BR (1) BR0206207A (https=)
CA (1) CA2464223C (https=)
CY (1) CY1109898T1 (https=)
DE (1) DE60230546D1 (https=)
DK (1) DK1461306T3 (https=)
ES (1) ES2315425T3 (https=)
MX (1) MXPA04003865A (https=)
MY (1) MY130316A (https=)
NO (1) NO20032938L (https=)
PT (1) PT1461306E (https=)
SG (1) SG168451A1 (https=)
WO (1) WO2003035599A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (en) 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
PT1461306E (pt) * 2001-10-26 2009-04-01 Pharmacia & Upjohn Co Llc Compostos de amónio quaternário
US7754242B2 (en) * 2002-03-20 2010-07-13 Alkermes, Inc. Inhalable sustained therapeutic formulations
WO2004000280A1 (en) * 2002-04-29 2003-12-31 Shire Laboraties, Inc. Pharmaceutical formulations with improved bioavailability
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
JP2006523676A (ja) * 2003-04-15 2006-10-19 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 第四級アンモニウム化合物と、その抗ムスカリン性剤としての使用
WO2004091597A2 (en) * 2003-04-15 2004-10-28 Pharmacia & Upjohn Company Llc Method of treating irritable bowel syndrome (ibs)
CA2522666A1 (en) * 2003-04-18 2004-10-28 Pharmacia & Upjohn Company Llc Combination therapies for chronic obstructive pulmonary disease (copd)
MXPA05011509A (es) 2003-04-25 2005-12-15 Pharmacia & Upjohn Co Llc 3,3-difenilpropilaminas (tolterodina) sustituidas con halogenos que presentan actividad antimuscarinica.
DE602004030931D1 (https=) 2003-11-04 2011-02-17 Supernus Pharmaceuticals Inc
US8709476B2 (en) 2003-11-04 2014-04-29 Supernus Pharmaceuticals, Inc. Compositions of quaternary ammonium compounds containing bioavailability enhancers
ES2235648B1 (es) * 2003-12-22 2006-11-01 Ragactives, S.L. Procedimiento para la obtencion de tolterodina.
EP1701932B1 (en) * 2003-12-24 2012-07-18 Cipla Ltd. Tolterodine, compositions and uses thereof, and preparation of the same
WO2005086873A2 (en) * 2004-03-11 2005-09-22 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
AU2005318426B2 (en) * 2004-12-24 2011-05-19 Lek Pharmaceuticals D.D. Process for preparation of 3-(2-hydroxy-5-methylphenyl)-N,N-diisopropyl-3-phenylpropylamine
CA2653105A1 (en) * 2006-05-24 2007-11-29 Boehringer Ingelheim International Gmbh Novel medicament combinations for the treatment of respiratory diseases
EP1908502A1 (en) * 2006-10-02 2008-04-09 Koninklijke Philips Electronics N.V. Interactive modular tile system
US7731604B2 (en) * 2006-10-31 2010-06-08 Taylor Made Golf Company, Inc. Golf club iron head
JP2010513277A (ja) * 2006-12-13 2010-04-30 ギリード・サイエンシズ・インコーポレーテッド COPDおよび慢性気管支炎の治療のためのムスカリン受容体アンタゴニストおよびβ−アゴニストの共通プロドラッグとしてのモノホスフェート
CA2675942C (en) * 2007-02-23 2016-04-12 Theravance, Inc. Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists
US8202891B2 (en) * 2007-04-24 2012-06-19 Theravance, Inc. Quaternary ammonium compounds useful as muscarinic receptor antagonists
US20090246146A1 (en) * 2008-01-25 2009-10-01 Botond Banfi Halides in the treatment of pathogenic infection
TW201010707A (en) * 2008-06-10 2010-03-16 Gilead Sciences Inc Corticosteroid linked beta-agonist compounds for use in therapy
WO2010010464A2 (en) * 2008-07-21 2010-01-28 Actavis Group Ptc Ehf Fesoterodine substantially free of dehydroxy impurity
JP5801997B2 (ja) 2009-07-07 2015-10-28 ファイザー・リミテッドPfizer Limited 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器
CN110372571B (zh) * 2018-04-12 2022-11-15 中国科学院大连化学物理研究所 一种2-(2,2-二芳基乙基)-环胺衍生物或盐及合成和应用与组合物
CN110845357B (zh) * 2019-11-22 2022-09-30 华东理工大学 季铵盐型酰肼化合物及由其制备的季铵盐型腙类化合物与应用
EP4171525A1 (en) 2020-06-26 2023-05-03 Mylan Pharma UK Limited Formulations including 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2592191A (en) * 1949-09-16 1952-04-08 Sterling Drug Inc Quaternary ammonium salts of nu-(3, 3-diphenylpropyl) pyrrolidine
US5382600A (en) * 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE106643C (https=)
NL124473C (https=) 1960-07-26
NL6717123A (https=) 1966-12-29 1968-07-01
US3505337A (en) 1967-12-22 1970-04-07 Boehringer Sohn Ingelheim N - hydrocarbyl-substituted noratropinium,haloalkylates and o-acyl derivatives thereof
IL91377A (en) 1988-09-14 1996-09-12 Nippon Shinyaku Co Ltd Derivatives of botinylamine glycolate
GB8906166D0 (en) 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
SE9203318D0 (sv) 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
US5492933A (en) 1993-10-08 1996-02-20 Sepracor, Inc. Methods and compositions for treating urinary incontinence and other disorders using optically pure R-terodiline and hydroxylated derivatives thereof
AU7971394A (en) 1993-10-08 1995-05-04 Sepracor, Inc. Method for treating urinary incontinence using optically pure s-terodiline
KR20000057548A (ko) 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재
SE9701144D0 (sv) 1997-03-27 1997-03-27 Pharmacia & Upjohn Ab Novel compounds, their use and preparation
PE20020547A1 (es) * 2000-10-24 2002-06-12 Upjohn Co Uso de la tolterodina en tratamientos del asma
JP2004512531A (ja) 2000-10-26 2004-04-22 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 電子デバイス
PT1461306E (pt) * 2001-10-26 2009-04-01 Pharmacia & Upjohn Co Llc Compostos de amónio quaternário
JP2006523676A (ja) * 2003-04-15 2006-10-19 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 第四級アンモニウム化合物と、その抗ムスカリン性剤としての使用
MXPA05011509A (es) * 2003-04-25 2005-12-15 Pharmacia & Upjohn Co Llc 3,3-difenilpropilaminas (tolterodina) sustituidas con halogenos que presentan actividad antimuscarinica.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2592191A (en) * 1949-09-16 1952-04-08 Sterling Drug Inc Quaternary ammonium salts of nu-(3, 3-diphenylpropyl) pyrrolidine
US5382600A (en) * 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
DK1461306T3 (da) 2009-03-09
MY130316A (en) 2007-06-29
US20050148672A1 (en) 2005-07-07
MXPA04003865A (es) 2004-07-08
US6890920B2 (en) 2005-05-10
DE60230546D1 (de) 2009-02-05
JP2005524605A (ja) 2005-08-18
EP1461306A1 (en) 2004-09-29
WO2003035599A1 (en) 2003-05-01
EP1461306B1 (en) 2008-12-24
CA2464223A1 (en) 2003-05-01
BR0206207A (pt) 2003-12-23
NO20032938D0 (no) 2003-06-26
NO20032938L (no) 2003-08-25
US20030158176A1 (en) 2003-08-21
ES2315425T3 (es) 2009-04-01
CA2464223C (en) 2009-05-26
ATE418534T1 (de) 2009-01-15
JP3981357B2 (ja) 2007-09-26
US7439397B2 (en) 2008-10-21
PT1461306E (pt) 2009-04-01
CY1109898T1 (el) 2014-09-10

Similar Documents

Publication Publication Date Title
SG168451A1 (en) Quarternary ammonium compounds and their use as antimuscarinic agents
BR0212733A (pt) Composto, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio afetivo
PA8546301A1 (es) Resolucion de sal quiral
BRPI0517515A (pt) composto de indolina e processo para produção do mesmo
AR047551A1 (es) Compuestos activos antritranspirantes de aluminio/ zirconio / glicina, estabilizados con betaina
MY145298A (en) Chemical process
MXPA05012286A (es) Mezclas fungicidas para combatir patogenos de arroz.
BR9714390B1 (pt) composição fungicida, processo para a preparação da referida composição e método para o combate de fungos.
ATE368023T1 (de) Hydroxydiphenyletherverbindungen
DE60332656D1 (de) Topische stabilisierte dosierungsformen für prostaglandin e-verbindungen
MXPA02009380A (es) Composicion de tenido que contiene un compuesto de para-aminofenol o para-fenilendiamina sustituido por un radical silanico.
PE120599A1 (es) Procedimiento para preparar compuestos quirales
BRPI0518976A2 (pt) mÉtodos para maximizar a retenÇço de partÍculas superabrasivas em uma matriz metÁlica
TR199901017A2 (xx) B�cek ilac� terkibi.
BR9707356A (pt) Composto processo para preparação do mesmo composição fingicida e processo para combater fungos
BRPI0408453A (pt) composto, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio afetivo
AU2002361185A1 (en) Use of (+)-(1s,2s)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol as anti-emetic agent
BR0312308A (pt) Mistura fungicida, agente fungicida, processo para combater fungos nocivos, e, uso dos compostos
BR0116853A (pt) Processo para a preparação de um composto, e, composto.
BR0311809A (pt) Mistura fungicida, agente fungicida, e, processo para combater fungos nocivos
MX9603133A (es) Acido para hidroxifenilacetico para la reduccion de la repelencia de insecticidas.
BR0312828A (pt) Mistura fungicida, agente fungicida, processo para combater fungos nocivos, e, uso de compostos
DE602005020396D1 (de) Haarfärbemittel enthaltend 2-Amino-3,5-substituierte Phenolverbindungen und deren Verwendung
BR0312307A (pt) Mistura fungicida, agente fungicida, processo para combater fungos nocivos, e, uso dos compostos
BRPI0418836A (pt) misturas fungicidas, agente fungicida, processo para combater fungos nocivos fitopatogênicos, semente, e, uso de compostos